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Multiple myeloma (MM) is the paradigmatic proteasome inhibitor (PI) responsive cancer, but many patients fail to
respond. An attractive target to enhance sensitivity is (macro)autophagy, recently found essential to bone marrow
plasma cells, the normal counterpart of MM. Here, integrating proteomics with hypothesis-driven strategies, we
identified the autophagic cargo receptor and adapter protein, SQSTM1/p62 as an essential component of an
autophagic reserve that not only synergizes with the proteasome to maintain proteostasis, but also mediates a plastic
adaptive response to PIs, and faithfully reports on inherent PI sensitivity. Lentiviral engineering revealed that SQSTM1 is
essential for MM cell survival and affords specific PI protection. Under basal conditions, SQSTM1-dependent autophagy
alleviates the degradative burden on the proteasome by constitutively disposing of substantial amounts of
ubiquitinated proteins. Indeed, its inhibition or stimulation greatly sensitized to, or protected from, PI-induced protein
aggregation and cell death. Moreover, under proteasome stress, myeloma cells selectively enhanced SQSTM1 de novo
expression and reset its vast endogenous interactome, diverting SQSTM1 from signaling partners to maximize its
association with ubiquitinated proteins. Saturation of such autophagic reserve, as indicated by intracellular
accumulation of undigested SQSTM1-positive aggregates, specifically discriminated patient-derived myelomas
inherently susceptible to PIs from primarily resistant ones. These aggregates correlated with accumulation of the
endoplasmic reticulum, which comparative proteomics identified as the main cell compartment targeted by autophagy
in MM. Altogether, the data integrate autophagy into our previously established proteasome load-versus-capacity
model, and reveal SQSTM1 aggregation as a faithful marker of defective proteostasis, defining a novel prognostic and
therapeutic framework for MM.
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Introduction
Multiple myeloma (MM) is the paradigmatic cancer suscepti-
ble to proteasome inhibitors (PIs), prototypical negative proteo-
stasis regulators.1 Accumulation of ubiquitin-protein conjugates
is a crucial mechanism in PI toxicity.2,3 Normal plasma cells
(PCs) acquire extreme vulnerability to PIs during their differenti-
ation, due to a dramatic reduction of proteasome capacity, which
does not meet the increased load of misfolded proteins requiring
proteasomal degradation, thereby triggering stress and lowering
the apoptotic threshold.4 This load-versus-capacity model con-
tributes to explain PI sensitivity in malignant PCs, as myelomas
with high proteasome capacity and low proteasome workload
show relative primary resistance.5 Indicative of cause-effect rela-
tionships, both increasing proteasome expression5 and attenuat-
ing protein synthesis6 specifically reduced vulnerability of
myeloma cells to the first-in-class PI bortezomib.
Despite the undisputed benefits of PIs, a proportion of PI-
na€ıve patients fail to respond,7-9 establishing a strong need to
develop biomarkers to identify patients more likely to benefit
from PI-based therapy. Notably, such biomarkers may offer tar-
gets for novel therapeutic approaches to achieve higher efficacy,
prevent side effects, and overcome resistance.2,10-12
Macroautophagy, conventionally referred to as autophagy, is a
conserved self-digestive lysosomal recycling pathway that sustains
cell metabolism under conditions of nutrient deprivation.13-15
Autophagy also mediates selective degradation of intracellular
supramolecular structures, including microbes (xenophagy), pro-
tein aggregates (aggrephagy), and organelles, thereby affording
innate defense, maintaining protein homeostasis (proteostasis),
and exerting critical quality control functions.16,17 In adaptive
immunity, selective autophagy mediates key tissue-specific func-
tions, including antigen presentation and T cell develop-
ment.18,19 Recently, we discovered that autophagy is essential to
ensure sustainable immunoglobulin (Ig) production in PCs,
through the selective restriction of the endoplasmic reticulum
(ER).20 Other groups have independently confirmed the essential
role of autophagy in sustaining antibody responses.21 Moreover,
we found that autophagy is absolutely required to maintain the
resident pool of bone marrow (BM) long-lived PCs, the normal
counterpart of MM.20
Autophagy is thought to play a 2-sided, context-dependent
role in cancer biology, oncosuppressive in normal cells, and pro-
tumoral in established cancers, which may exploit autophagy to
resist stress.22 In cellular and animal models of proteotoxicity,
autophagy compensates for proteasome insufficiency by clearing
protein aggregates.15,23,24 Myeloma cells are thus thought to be
particularly dependent on autophagy owing to their distinctive
overloaded ubiquitin (Ub)-proteasome system (UPS).10-12
Hence, defining the constitutive levels, exact homeostatic func-
tions and molecular mechanisms of autophagy in MM cells is
needed to design specific strategies to disarm this cancer.
Selective autophagic degradation is achieved through proteins
that act as specific cargo receptors, which crosslink the substrate
with the autophagic machinery. The prototypical receptor,
SQSTM1/p62, is a multifunctional signaling adapter protein
that has been implicated in a number of selective autophagic
processes.17
In the present work, we investigated the role of SQSTM1 in
the maintenance of protein homeostasis in MM cells. By com-
bining unbiased proteomics and hypothesis-driven technologies,
we identified a SQSTM1-dependent autophagic reserve that not
only cooperates with the UPS for the clearance of Ub-protein
conjugates, but is also capable of adapting to proteasome stress,
through enhanced SQSTM1 expression and a profound reshap-
ing of its interactome, revealing a tighter collaboration between
the UPS and autophagy than previously thought. As a result,
SQSTM1 is critical for MM cell survival, and its inhibition sensi-
tizes to PIs. Moreover, the presence of SQSTM1-containing pro-
tein aggregates emerges as a novel potential biomarker of PI
susceptibility of therapeutic and prognostic value.
Results
Intense autophagy constitutively degrades ubiquitinated
proteins to prevent accumulation of SQSTM1-positive protein
aggregates in myeloma cells
To quantify overall autophagic activity in MM cells, we
assessed the rate of lysosomal digestion of lipidated, autophago-
some-bound MAP1LC3A/LC3A (LC3A-II) in a panel of 6 MM
lines. All 6 cell lines showed intense autophagic fluxes (Fig. 1A).
In particular, their autophagic activity was 5- to 50-times higher
than in the B lymphomas MEC1 (Fig. 1A) and RAJI (not
shown). Stable lentiviral silencing of the essential autophagic
molecule ATG7 confirmed the critical role of autophagy in
maintaining MM cell survival (Fig. S1).25,26
To address the function of such intense constitutive autoph-
agy, we asked if it mediates the clearance of Ub-conjugated pro-
teins in MM cells. Distal pharmacological inhibition of
autophagy induced remarkable accumulation of heterogeneous
ubiquitinated proteins and of the prototypical autophagic recep-
tor, SQSTM1 (Fig. 1B). Immunofluorescence experiments
revealed Ub-protein aggregates that colocalized with SQSTM1
(Fig. 1C). Moreover, autophagy blockade led to a remarkable
increase in the number and size of SQSTM1C cytoplasmic aggre-
gates (Fig. 1D), and induced substantial accumulation of
SQSTM1 in detergent-insoluble cellular fractions (Fig. 1E). The
data demonstrate abundant and constitutive autophagic clearance
of ubiquitinated proteins in MM cells, and suggest SQSTM1 as
the receptor involved in such clearance.
Collaboration of the proteasome and autophagy to maintain
protein homeostasis and viability of MM cells
The finding that autophagy constitutively contributes substan-
tial clearance of ubiquitinated proteins suggests that it may play a
crucial role in alleviating proteasome stress in MM cells, if sub-
strates were shared with the UPS. To test this hypothesis, we
attempted to increase or reduce PI toxicity, respectively, by weak-
ening or empowering autophagy. Treatment with nontoxic doses
of bortezomib and the distal authophagy inhibitor leupeptin
yielded dramatic accumulation of Ub-protein conjugates and
1162 Volume 11 Issue 7Autophagy
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 de
gli
 St
ud
i d
i T
or
ino
] a
t 0
4:1
2 1
1 J
an
ua
ry
 20
16
 
Figure 1. Autophagy inhibition leads to accumulation of SQSTM1C undigested protein aggregates in MM cells. (A) Immunoblot analysis of endogenous
unconjugated LC3-I to lipid-conjugated LC3-II and SQSTM1 in multiple myeloma (MM) cell lines. The MEC1 lymphoma and the indicated MM cell lines
were treated for 2 h with 50 mM NH4Cl or left untreated, lysed in 1% SDS and analyzed by western blot with anti-LC3 Ab (left). ACTB/actin serves as a
loading control throughout. Right, autophagic flux quantified as the difference of LC3-II band intensity with and without NH4Cl, normalized on MEC1 val-
ues (average §s.e.m., n D 5). (B) Immunoblot analysis of ubiquitinated proteins, SQSTM1 and LC3 in MM cells treated with 100 nM bafilomycin A1 (Baf
A1) for 24 h (representative image, n D 3). (C) Immunofluorescence analysis of SQSTM1 (green) and ubiquitin (red) in MM.1S cells. Nuclei are stained
blue with DAPI. Scale bars: 10 mm. (D) Immunofluorescence analysis of SQSTM1 and ubiquitin in MM.1S and OPM2 cells treated with chloroquine (50
mM) or bafilomycin A1 (100 nM) for 24 h. Nuclei are stained blue with DAPI. Scale bars; 10 mm. (E) Representative immunoblot analysis of SQSTM1 in MM
cells treated with 100 nM Baf A1 for 24 h and lysed in 1% NP-40. Insoluble material was treated with 1% SDS and the DNA was sonicated. NP-40 soluble
and insoluble fractions were quantified and equal protein amounts resolved by SDS-PAGE.
www.tandfonline.com 1163Autophagy
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Figure 2. For figure legend, see page 1165.
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insoluble SQSTM1 (Fig. 2A–B), which preceded massive syner-
gistic cell death in MM lines (Fig. 2C) and in primary, patient-
derived MM cells (Fig. 2D). Conversely, stimulation of autoph-
agy substantially prevented PI-induced accumulation of Ub-pro-
teins (Fig. 2E) and the subsequent death of MM cells (Fig. 2F-
G). The data establish that in myeloma cells autophagy coopera-
tes with the proteasome, sharing Ub-protein substrates, and limits
PI sensitivity. However, in our hands, autophagic inhibition by
lentiviral ATG7 silencing or by hydroxychloroquine (HCQ)
caused minor increases of bortezomib-induced toxicity in MM
cell lines (Figs. S1F and S2). The data also suggest that, by inte-
grating stress of both the UPS and autophagy, accumulation of
insoluble SQSTM1 (Fig. 2B and E) may predict proteotoxicity.
SQSTM1 is essential to myeloma cells and yields specific
protection against proteasome inhibitors
In view of the tight cooperation of the UPS and autophagy
documented in MM cells, we next challenged the relevance of
SQSTM1 in myeloma cell viability and PI sensitivity. To this
aim, we achieved stable SQSTM1 silencing by lentiviral shRNA
expression. Reduction of SQSTM1 protein abundance in MM
cell lines (Fig. 3A and Fig. S3A) induced significant decrease of
intracellular ATP (Fig. 3B) and remarkable toxicity, with mas-
sive death of SQSTM1-silenced MM lines in less than 2 wk, as
assessed by apoptosis and colony-forming assays (Fig. 3C, D and
Fig. S3B). Conversely, a comparable reduction of SQSTM1
expression in 2 B lymphomas elected as controls (Fig. 3A)
induced significantly less or negligible death (Fig. 3C), suggest-
ing that SQSTM1 requirement is specific to PCs. We then
exploited the timeframe preceding overt toxicity to test if
SQSTM1 confers specific protection against PIs. Prior to the
onset of cell death, SQSTM1-silenced MM cells revealed signifi-
cantly increased susceptibility to bortezomib-induced accumula-
tion of ubiquitinated proteins and toxicity (Fig. 3E, F and Fig.
S3C). The protective activity of SQSTM1 was specific, as its
reduction failed to affect the toxicity of the distinct anti-myeloma
agent doxorubicin (Fig. 3F). Thus, MM cells require SQSTM1
for survival and specific inherent resistance to PIs.
Proteasome stress co-opts SQSTM1 onto protein aggregates
and induces de novo SQSTM1 expression
The increased sensitivity of SQSTM1-silenced MM cells to PIs
urged us to address the mechanisms whereby SQSTM1 mediates
PI resistance in MM cells. Along with its role as an autophagic
receptor, SQSTM1 is a multi-tasking adapter protein regulating
multiple signaling pathways. We thus examined its expression,
distribution, and activity under proteasome stress. Short (1 h)
treatment with a high dose (1 mM) of the first-in-class PI borte-
zomib induced the appearance of large (»100 nm to >1 mm)
SQSTM1C aggregates in MM cells (Fig. 4A), with a UbC core
surrounded by SQSTM1 (Fig. 4B). Immunoprecipitation (IP)
experiments demonstrated the specific interaction of SQSTM1
and ubiquitinated proteins. Such interaction was magnified by
PIs, while the prototypic interaction with KEAP1, which pro-
motes NFE2L2/NRF2-dependent anti-oxidant responses, was
greatly reduced (Fig. 4C). We then adopted stable isotope label-
ing in cell culture (SILAC) proteomics to precisely quantify the
changes of the SQSTM1 interactome upon proteasome inhibi-
tion (experimental design illustrated in Fig. S4A, B). Under basal
conditions, SQSTM1 bound a number of known interactors,
e.g., KEAP1, PRKCI, and Ub (Table 1). Noticeably, proteasome
inhibition induced a dramatic change of the SQSTM1 interac-
tome, with Ub increasing by »10 times, at the expense of other
interactors (Fig. 4D and Table 1). Moreover, SQSTM1 expres-
sion analyses revealed that bortezomib also selectively increased
de novo expression of SQSTM1, but not of the autophagic recep-
tors NBR1 and OPTN/optineurin, as demonstrated by increased
transcript and protein levels (Fig. 4E, F and Fig. S4C), an effect
independent of autophagy (attested to by no consistent change in
LC3 conversion in Fig. 4F) and completely prevented by inhibi-
tion of protein translation (Fig. 4G). Together, the data reveal a
previously unrecognized 2-fold adaptive response deployed by
MM cells under proteasome stress, consisting of rapid co-opting
of SQSTM1 onto Ub-protein aggregates, at the expense of its sig-
naling activities, and enhanced SQSTM1 expression.
SQSTM1C protein aggregates specifically predict
proteasome inhibitor susceptibility in MM lines and patient-
derived myelomas
Having identified a key protective role for SQSTM1 in medi-
ating the autophagic degradation of proteasome-undigested Ub-
proteins in MM cells (Fig. 4), and in view of the strong correla-
tion between SQSTM1 aggregation and subsequent toxicity
observed in vitro (Fig. 2), we then explored the prognostic signif-
icance of SQSTM1 as a biomarker of primary PI susceptibility.
This idea stemmed from 2 observations: first, that PI-sensitive
Figure 2 (See previous page). The proteasome and autophagy synergize to maintain protein homeostasis and viability of MM cells. (A–D) Inhibition of
autophagy sensitizes MM cells to PI-induced accumulation of Ub-proteins and cell death. (A) Immunoblot analysis of ubiquitinated proteins in MM lines
treated with the indicated doses of bortezomib (Btz) and leupeptin (Leu), alone or combined, for 24 h (representative blots of 3 independent experi-
ments). (B) Immunoblot analysis of SQSTM1 in OPM2 cells left untreated or treated for 24 h with the indicated doses of Btz and Leu (20 mM), alone or
combined. Equal amounts of NP-40 soluble and insoluble fractions were loaded and resolved by SDS-PAGE. Top, representative blots; bottom, quantifica-
tion of 3 independent experiments (average §s.e.m.). (C) MM lines were treated with the indicated doses of Btz and Leu, alone or combined, for 48 h,
and cell viability assessed by flow cytometry upon propidium iodide and ANXA5 staining (average quantification of ANXA5 positive cells §s.e.m, n D 4).
(D) MM cells were immunomagnetically sorted from BM aspirates obtained from newly diagnosed patients treated for 24 h with 2 or 5 nM Btz and 10
mM Leu, alone or combined, and cell viability assessed by flow cytometry after staining with propidium iodide and ANXA5 (average quantification of
ANXA5-positive cells §s.e.m.; n D 9 patients). (E–G) Stimulation of autophagy protects MM cells from PI-induced build-up of ubiquitinated proteins and
cell death. (E) Immunoblot analysis of SQSTM1, LC3 and ubiquitinated proteins in MM.1S cells treated for 24 h with the indicated dose of rapamycin
(Rapa), in the presence or absence of bortezomib (Btz) for the last 8 h (n D 3). (F) The viability of cells treated as in (E) for 24 h was assessed by flow
cytometry upon propidium iodide and ANXA5 staining (average quantification of double negative cells §s.e.m., n D 4). (G) Representative density plot
of propidium iodide and ANXA5 staining in Rapa and/or Btz-treated MM.1S cells. *P < 0 .05; **P < 0 .01; ***P < 0 .001; unpaired Student t test.
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Figure 3. For figure legend, see page 1167.
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MM.1S cells displayed SQSTM1C aggregates in basal condi-
tions, whereas relatively resistant OPM2 cells did not (Fig. 1);
second, that SQSTM1 aggregation preceded cell death upon
treatment with toxic doses of proteasome and autophagy inhibi-
tors, alone or in combination (Fig. 2). Hence, we hypothesized
that SQSTM1 aggregation could serve as a reliable marker of
insufficient autophagic reserve and proteotoxicity.
To test this hypothesis, we extended the immunofluorescence
and biochemical analyses of SQSTM1 accumulation to a panel
of 11 MM lines, hallmarked by differential intrinsic sensitivity to
bortezomib, as determined in standard 24-h apoptotic response
curves (Fig. S5A). Immunoblotting experiments showed remark-
able accumulation of SQSTM1 in the lines characterized by
lower EC50 values (Fig. 5A, left panel and Fig. S5B). Moreover,
we found SQSTM1 in detergent-insoluble fractions and in
immunofluorescent aggregates exclusively in the most PI-sensi-
tive lines (Fig. 5A, right, 5B, and Fig. S5C). Accumulation of
SQSTM1C aggregates specifically reported on defective proteo-
stasis, as the average cell count of SQSTM1C puncta in each line
correlated significantly with the EC50 of bortezomib (Fig. 5C),
but not with that calculated with the distinct anti-myeloma
agent, dexamethasone (Fig. 5D).
We then challenged the significance of SQSTM1C puncta in
primary MM cells purified from newly diagnosed MM patients.
Notably, also in patient-derived cells, we could neatly discrimi-
nate between myelomas that do or do not display SQSTM1C
puncta (Fig. 5E). The presence of SQSTM1C structures identi-
fied the myelomas with the highest susceptibility to bortezomib
in vitro (i.e., EC50 5 nM) (Fig. 5F). Moreover, the average cel-
lular count of SQSTM1C puncta within each tumor population
significantly correlated with the EC50 of bortezomib determined
in vitro (Fig. 5G). The coincidence of accumulation of
SQSTM1C aggregates with exquisite inherent PI sensitivity also
in primary samples confirms saturation of a putative protective
autophagic reserve. The data provide proof-of-principle evidence
and pre-clinical validation of SQSTM1 aggregation as a single-
cell indicator of intrinsic susceptibility to PIs.
A proteostatic autophagic reserve is saturated in PI-sensitive
myelomas
The observation of SQSTM1 aggregation selectively in most
PI-sensitive myelomas (Fig. 5) suggested the existence of a func-
tional autophagic reserve saturated in basal conditions in those
tumors. Indeed, when we challenged a panel of MM lines with
low dose (5 nM) bortezomib, relatively PI-resistant lines did not
accumulate ubiquitinated proteins, while PI-sensitive cells did,
despite the fact that comparable proteasome inhibition had been
achieved (Fig. 6A, B). To test if this differential proteostatic
reserve is accounted for by autophagy, we utilized pharmacological
and genetic inhibition. In keeping with our hypothesis, immuno-
fluorescent detection of SQSTM1C puncta revealed defective
autophagic clearance of bortezomib-induced aggregates in PI-sen-
sitive MM lines (Fig. 6C, D). Immunoblotting experiments con-
firmed that bortezomib was sufficient to induce the accumulation
of insoluble SQSTM1 in PI-sensitive MM lines, whereas the distal
autophagy inhibitor bafilomycin A1 was required to induce accu-
mulation of insoluble SQSTM1 in PI-resistant cells (Fig. 6E).
Indeed, in these cells, inhibition of autophagy, as achieved by
cotreatment with leupeptin or by previous lentiviral ATG7 RNAi,
maximized the limited accumulation of ubiquitinated proteins
induced by subtoxic proteasome stress (Fig. 6F). Together, these
experiments formally demonstrate the existence, in MM cells, of
an autophagic reserve required to cope with PI-induced proteotox-
icity and maintain proteostasis, and that such reserve is saturated
in PI-sensitive myelomas.
The ER is a major autophagic substrate that accumulates in
PI-sensitive myelomas
The observation that SQSTM1-containing aggregates hall-
mark certain myelomas, but not all (Fig. 5), raises the question
as to whether additional targets burden autophagy. We recently
discovered that the ER is the main cell compartment degraded by
autophagy in normal PCs.20 To test if reticulophagy is a major
autophagic task also in malignant PCs, we adopted an unbiased
proteomic approach to define the cell compartments that are con-
stitutive targets of autophagy in MM cells. We first studied
OPM2 cells, in which SQSTM1 degradation and autophagy are
most proficient, and then extended our observations to other cell
lines. The proteome of OPM2 cells was labeled by SILAC and
the changes of individual proteins upon pharmacological autoph-
agy inhibition quantified by LC-MS/MS. We achieved distal
autophagy blockade by treating MM cells for 24 h with the lyso-
somal inhibitor leupeptin at a dose that arrested the autophagic
flux (Fig. S6A), causing no toxicity (loss of ATP or viability), no
proteasome stress (accumulation of Ub-proteins), and no adap-
tive activation of the unfolded protein response (UPR) (Fig.
S6B–E). In 2 different experiments with inverted isotope label-
ing, we identified 981 proteins with at least 2 peptides quantified
Figure 3 (See previous pge). SQSTM1 is essential for MM cell survival and affords specific protection against proteasome inhibitors. (A) Immunoblot
analysis of SQSTM1 in the indicated myeloma and lymphoma cell lines 4 d after infection with lentiviral vectors expressing anti-SQSTM1 and control
shRNAs (representative blots, n D 3). (B) Intracellular ATP in fresh lysates from OPM2 and MM.1S cells 4 d post SQSTM1 silencing (average §s.e.m., n D 4,
normalized to cell number). (C) The indicated MM and B lymphoma cell lines were infected with lentiviruses co-expressing shRNA against SQSTM1 or con-
trol shRNA, and GFP, and the percentage of live GFPC cells expressing anti-SQSTM1 shRNA was assessed at the indicated timepoints by flow cytometry
upon propidium iodide and ANXA5 staining, and normalized by the frequency of live GFPC cells expressing control shRNA. (D) Soft agar colony-forming
assay on MM cells 4 d after lentiviral infection. After 21 d colonies were stained with thiazolyl blue tetrazolium bromide and counted by light microscopy
(average number of colonies per field §s.e.m.). (E) Immunoblot analysis of ubiquitinated proteins in OPM2 cells 4 d after lentiviral infection treated for
8 h with the indicated dose of bortezomib (n D 3). (F) Apoptotic sensitivity to 24 h treatment with the indicated doses of bortezomib and doxorubicin in
GFPC SQSTM1-silenced and control OPM2 cells was assessed by flow cytometry, as above, and expressed as the percentage of propidium iodide- and/or
ANXA5-positive cells, normalized to untreated cells (n D 6). Similar results were obtained with MM.1S cells. *P < 0 .05; ***P < 0 .001; unpaired Student t
test.
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in both experiments (Dataset S1). We found 45 proteins consis-
tently and significantly upregulated by leupeptin. These included
established components of the secretory apparatus, such as
LMAN1/ERGIC53, ERP44, and RAB7A (Table S1). Gene
ontology (GO) analysis of upregulated proteins among the 981
quantified found significant specific enrichment of ER-resident
proteins (GO:0005789; p D 0.041) and the Golgi apparatus
(GO:0005794; p D 0.039), together with the expected lysosomal
compartment (GO:0005764; p D 0.024). By extending the GO
analysis to all quantified proteins, we found lysosomal inhibition
to induce a concerted, significant
increase of ER membrane pro-
teins (n D 32, average increase
4.3%), ERGIC (n D 12, average
increase 7.6%) and Golgi (n D
60, average increase 6.6%). Con-
versely, no increase was found in
ribosomal, nuclear and cytosolic
proteins, whereas a slight, con-
certed increase was detected for mitochondrial proteins (n D
167, average increase 0.7%) (Fig. 7A). A significant increase of
selected components of the secretory apparatus was also con-
firmed upon genetic inhibition of autophagy in ATG7-silenced
MM cells by immunoblotting (Fig. S6F). Also in this indepen-
dent setting, we excluded autophagy inhibition to induce a UPR,
by documenting no increase of total and spliced XBP1, P4HB/
PDI, and HSPA5/BiP mRNA (Fig. S6G), further confirming
that ER expansion stemmed from defective protein digestion,
rather than from increased biogenesis. The data demonstrate a
Figure 4. Acute proteasome stress
co-opts SQSTM1 onto protein aggre-
gates, and induces de novo SQSTM1
expression. (A, B) Immunofluores-
cence analysis of SQSTM1 and ubiq-
uitin accumulation in MM lines upon
treatment with bortezomib (Btz).
Nuclei are stained blue with DAPI.
Scale bars: 10 mm. (A) SQSTM1 in
MM.1S cells left untreated (left) or
treated for 1 h with 1 mM Btz (right)
(n D 5 independent experiments).
(B) SQSTM1 and ubiquitin in MM.1S
cells treated with Btz (as in A). (C)
Co-immunoprecipitation (IP) of poly-
ubiquitinated proteins with SQSTM1.
MM.1S cells were treated with Btz
(as in A), prior to IP of SQSTM1, and
the association of ubiquitinated pro-
teins and KEAP1 with SQSTM1
assessed by immunoblot (n  3 ).
(D) Changes of selected proteins of
the SQSTM1 interactome upon treat-
ment with Btz (as in A) as deter-
mined by SILAC LC-MS/MS in MM.1S
cells (more proteins listed in
Table 1). (E) Quantitative RT-PCR
analysis of transcripts encoding the
indicated autophagy receptors in
MM lines treated with 1 mM Btz for
4 h. mRNA amounts were normal-
ized by histone H3 and expressed
relative to untreated controls (aver-
age induction §s.e.m.; n D 3). (F)
Immunoblot analysis of SQSTM1 and
LC3 in the indicated MM lines
treated with 1 mM Btz for 8 h (repre-
sentative blot, n D 3). (G) Immuno-
blot analysis of SQSTM1 in MM.1S
cells treated with 1 mM Btz for 8 h in
the presence or absence of 10 mg/
ml cycloheximide (CHX).
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selective negative control exerted by autophagy on the secretory
pathway in MM cells, previously recognized only in normal
PCs.20 Interestingly, we found that Ig molecules did not accumu-
late upon lysosomal inhibition, indicating that misfolded Igs are
recycled via the canonical proteasomal ER-associated degrada-
tion, at least in light chain-producing myeloma cells (Fig. S7;
Table S2), confirming our previous findings in normal plasma
cells.20 Next, we confirmed that autophagy negatively regulates
the ER in a panel of MM lines by revealing increased abundance
of representative ER resident proteins upon pharmacological
autophagic inhibition (Fig. 7B).
Having identified the ER as a major autophagic substrate in
MM cells, we then hypothesized the saturated autophagic
reserve identified in relatively PI-sensitive myelomas, as indi-
cated by SQSTM1C aggregates, to be associated with higher ER
abundance. To test this hypothesis, we performed a proteomic
and morphological comparison, respectively by SILAC LC-MS/
MS and electron microscopy, of the MM lines containing
respectively the highest and lowest number of SQSTM1C
puncta per cell, namely MM.1S and OPM2 cells. This com-
bined approach revealed higher abundance of the ER in
MM.1S cells (Fig. 7C-D; Dataset S2; Table S3). We confirmed
this finding by immunoblotting analyses of representative ER
proteins that were significantly more abundant in PI-sensitive
than in PI-resistant MM lines (Fig. 7E).
By identifying the ER as themain cell compartment constitutively
degraded by autophagy in MM cells, whose accumulation correlates
with SQSTM1-containing aggregates, the data confirm that the
autophagic capacity is saturated in inherently PI-sensitive myelomas.
Together, the data provide a more comprehensive and inte-
grated picture of the cellular determinants of proteostasis and PI
sensitivity in myeloma cells.
Discussion
The role of autophagy in cancer is multifaceted. In keeping
with its cytoprotective action, loss-of-function mutations of genes
encoding autophagic players have been linked with tumorigene-
sis, supporting the notion that autophagy is oncosuppressive in
normal cells.22,27 The underlying mechanisms include the dis-
posal of oncogenic proteins and damaged organelles, preventing
local inflammation, necrosis, accumulation of reactive oxygen
species, and oncogenic mutations.28-31 Conversely, due to
deregulated growth, cancer cells generally experience more stress
(e.g., hypoxia, nutrient deprivation, oxidative stress) and rely on
adaptive strategies more than normal cells.32,33 Autophagy may
thus be essential for transformed cells to resist metabolic, envi-
ronmental, and pharmacological stress. Hence, autophagy inhibi-
tors may be effective against cancer by killing tumor cells or
sensitizing them to chemotherapy.22
In addition, specific metabolic features could render certain
tumors particularly dependent on autophagy. This applies to
RAS-driven cancers, owing to impaired acetyl-CoA biosynthe-
sis.22 Myeloma has been proposed to be particularly reliant on
autophagy, due to its extraordinary UPS dependence, demon-
strated by the successful clinical use of PIs,2 owing, at least in
part, to an imbalance between high proteasome workload, con-
tributed by intensive Ig synthesis, and limited proteasome com-
plement.5,34 Such imbalance is a general trait of Ig-producing
PCs, which are also extremely PI-sensitive in vitro4 and in
vivo.35,36 Long viewed as independent strategies with distinct
substrates, the UPS and autophagy are now recognized as interde-
pendent and complementary. Indeed, autophagy is activated in
response to, and partially compensates for, proteasome
impairment.15,23,24
Table 1. The interactome of SQSTM1 in basal conditions and under proteasome stress
Protein Gene name SQSTM1/Control ratio Btz/UT ratio
sequestosome 1 SQSTM1 10.38 1
kelch-like ECH-associated protein 1 KEAP1 9.67 0.57
ependymin related 1 EPDR1/UCC1 9.19 0.68
glioblastoma amplified sequence GBAS 8.71 0.25
insulin receptor INSR 8.07 3.12
protein kinase C, iota PRKCI 5.60 0.87
NOP2/Sun domain family, member 4 NSUN4 4.65 0.32
growth arrest-specific 6 GAS6 4.23 0.68
tripartite motif containing 21 TRIM21 3.62 1.91
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase) NDUFS2 3.04 0.62
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) NDUFS3 2.82 0.51
G elongation factor, mitochondrial 2 GFM2 2.71 2.29
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein),
b subunit
HADHB 2.54 2.60
NADH dehydrogenase (ubiquinone) 1 a subcomplex, 5 NDUFA5 2.50 1.16
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein),
a subunit
HADHA 2.28 1.93
CD48 molecule CD48 2.13 0.68
lactate dehydrogenase A LDHA 2.09 1.57
reticulocalbin 2, EF-hand calcium binding domain RCN2 2.08 1.09
ubiquitin UBC; UBB 2.05 9.93
Specific SQSTM1 interactors with a SQSTM1/control ratio > 2. Bortezomib (Btz) / untreated (UT) ratios indicate relative interaction changes upon treatment.
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Figure 5. For figure legend, see page 1171.
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The results presented herein are in keeping with previous
reports supporting a protective role for basal autophagy in MM
cell survival. However, pharmacological or genetic autophagic
inhibition yielded discrepant results on PI sensitivity, ranging
from synergy to antagonism.10,25,26,38,39 Notably, a phase 1 clini-
cal trial showed that the combined use of bortezomib and HCQ
for relapsed or refractory myeloma may improve therapeutic out-
comes.40 In our hands, autophagy inhibition with leupeptin or
SQSTM1 RNAi sensitized to bortezomib, and autophagy induc-
tion with rapamycin reduced PI sensitivity (Figs. 2 and 3), but
HCQ and ATG7 RNAi had no remarkable effects on PI toxicity
(Figs, S1–S2). Such controversies might in part be accounted for
by nonspecific effects achieved on additional signaling pathways,
especially in the case of proximal autophagic inhibition.
Despite the general belief that autophagy inhibition should be
beneficial against myeloma,10,11 we reasoned that our current
poor understanding of the role of autophagy in this malignancy
limits its therapeutic exploitation. Our recent discovery that
long-lived plasma cells completely depend on autophagy20 urged
us to dissect the precise functions of autophagy in myeloma, to
identify specific cargo-recognizing mechanisms, as a framework
for novel markers and targets.
Autophagy serves a variety of cell-specific functions through
selective target digestion via distinct receptor/adapter proteins.41
We thus set out to test the role of the prototypical autophagic
receptor, SQSTM1 in MM cells, assuming that a deeper knowl-
edge of the molecular mechanisms of cargo selection may offer a
framework to design more specific therapeutic agents.
Our work establishes SQSTM1 as an essential mediator of the
cooperation between the UPS and autophagy in MM cells, pro-
viding a potential target to overcome PI resistance. First, we
found that autophagy constitutively degrades aggregation-prone
ubiquitinated proteins, as autophagy inhibition alone was suffi-
cient to induce the accumulation of SQSTM1- and Ub-contain-
ing protein aggregates (Figs. 1 and S2). The relevance of
SQSTM1-dependent autophagy as a functional reserve regulat-
ing PI susceptibility of MM cells is demonstrated by the docu-
mented capacity of autophagy inhibition or stimulation to
respectively synergize or antagonize with the PI-induced build-
up of ubiquitinated proteins and subsequent toxicity (Fig. 2).
The coexistence of SQSTM1 aggregation and abundant autoph-
agy in PI-sensitive myelomas in basal conditions suggests that
certain tumors require more autophagic activity than they
deploy. Indeed, an increased demand imposed by acute
proteasome stress is coped for by autophagy in PI-resistant MM
cells, while aggravating accumulation of SQSTM1C aggregates
in PI-sensitive myelomas (Fig. 6). Taken together, our results
yield proof-of-concept evidence in PI-sensitive myelomas of an
insufficient autophagic reserve in the face of stresses that increase
the functional demand for autophagy.
Moreover, we disclosed that MM cells adapt to proteasome
stress via SQSTM1. We devised, for the first time, a wide-scope,
quantitative LC-MS/MS analysis of proteins co-immunoprecipi-
tated with endogenous SQSTM1 to define the interactome of
SQSTM1 in steady conditions and under proteasome stress,
using the SILAC technology to precisely quantify PI-induced
changes. Together with immunofluorescence experiments, this
powerful, unbiased approach led us to recognize the association
of Ub-protein aggregates with SQSTM1 in myeloma cells. More-
over, we visualized aggregates nucleating into large, supra-micro-
metric bodies under PI treatment, and found a dramatic co-
opting of SQSTM1 onto Ub-protein aggregates at the expense of
other signaling partners. As a multi-domain adapter protein,
SQSTM1 is a hub for multiple signaling pathways, including
NFKB and KEAP1-NFE2L2, along with its recognized role in
autophagic cargo recognition.42,43 Our unbiased dynamic study
of the SQSTM1 interactome revealed an intriguing adaptation of
MM cells to proteasome stress, aimed to intensify the autophagic
activity of this protein. Furthermore, we found that PIs not only
divert SQSTM1 toward ubiquitinated proteins, but also selec-
tively induce its de novo expression (Fig. 4). Together, these
mechanisms define an unanticipated 2-fold adaptive plastic
response to PIs, by which myeloma cells boost autophagic degra-
dation of aggregates to compensate for UPS insufficiency. The
data indicate that in MM cells autophagy and the UPS cooperate
more closely than previously thought, as both constitutively
degrade Ub-conjugated proteins, and provide insights into the
nature and mechanisms of this cooperation. By furthering our
understanding of the tight interplay between autophagy and the
UPS,44 these findings may help explain PI resistance and unveil
new therapeutic targets. Indeed, the genetic ablation of SQSTM1
resulted in increased susceptibility to PIs and in vitro extinction
of MM cell lines (Fig. 3).
Functional redundancy exists among autophagic receptors,17
as witnessed by the nonlethal mouse phenotype of systemic
SQSTM1 deficiency,45 and by the tissue-restricted and late-onset
phenotype of Paget disease of bone, typically associated with
germline inactivating mutations of the Ub-binding domain of
Figure 5 (See previous page). Spontaneous SQSTM1 aggregation specifically predicts bortezomib susceptibility in MM cell lines and in patient-purified
myeloma cells. (A) Left panel: Immunoblot analysis of SQSTM1 on 1% SDS lysates from MM lines (representative blots, n D 3). Right panel: MM cells were
lysed in 1% NP-40, insoluble material was resuspended in 1% SDS and the DNA was sonicated; equal protein amounts from NP-40 soluble and insoluble
fractions were resolved by SDS-PAGE. Representative blots are shown (n D 3). (B) Immunofluorescence analysis of SQSTM1 accumulation in MM lines.
Nuclei are stained blue with DAPI. Scale bar: 10 mm. Representative images. (C, D) Linear Pearson’s correlation between the average cellular counts of
SQSTM1C dots (n  80 cells in 10 distinct fields) and the log EC50 of bortezomib (C, as assessed in Fig. S5, n D 11) or that of dexamethasone (D, as
assessed upon 48 h treatment). (E) Immunofluorescence analysis of SQSTM1 accumulation in SDC1/CD138C cells purified from BM aspirates of 6 repre-
sentative newly diagnosed MM patients. Nuclei are stained blue with DAPI. Scale bars: 10 mm. (F) Apoptotic sensitivity to 24-h treatment with bortezomib
was assessed in vitro by flow cytometry, as in Fig. S5 (n D 9). The panel shows 6 representative MM patients as in (E). (G) Linear Pearson’s correlation
between the average cellular counts of SQSTM1C dots in each patient and the log EC50 of bortezomib (n D 9 patients).
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Figure 6. For figure legend, see page 1173.
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SQSTM1.46 Thus, the absolute requirement of SQSTM1 for
MM cell survival offers a specific therapeutic target, and a frame-
work for identifying additional new targets.
Further supporting specificity, while SQSTM1 is protective to
MM cells, it demonstrates toxicity in distinct models, possibly via
hampered proteasomal degradation of substrates sequestered into
insoluble aggregates.47 In mice with liver-specific ablation of
autophagy, SQSTM1 silencing prevents protein aggregation, oxi-
dative stress, and tissue hypertrophy.48 Such toxicity of SQSTM1
was suppressed by NFE2L2 ablation, suggesting that the other-
wise protective SQSTM1-KEAP1-NFE2L2 axis may turn mal-
adaptive in certain conditions.49 The addiction of MM cells to
SQSTM1-dependent autophagy for survival, identified herein,
may reflect the fragile proteostasis of malignant PCs, already
challenged in the absence of exogenous stressors, with overloaded
UPS, high PI vulnerability, and intense autophagy.12 Accord-
ingly, we found that SQSTM1 silencing was extremely toxic for
MM cell lines, but not for B lymphomas, and that its knockdown
specifically sensitized MM cells to the first-in-class PI bortezo-
mib, but not to other anti-myeloma agents (Fig. 3). The mecha-
nisms whereby insufficient SQSTM1-dependent autophagy is
toxic to MM cells remain to be elucidated. A recent report of
BIK-mediated apoptosis triggered by SQSTM1 downregulation
upon autophagy induction suggests a possible mechanism.50
Through unbiased analyses of cells in which autophagy had
been blocked pharmacologically or genetically, our work dis-
closed that in MM cells autophagy not only disposes of aggrega-
tion-prone ubiquitinated proteins, but also constitutively restricts
the secretory compartment, a previously unrecognized function
in MM cells (Fig. 7). Both activities are predicted to reduce the
UPS workload.2,12 The data extend our previous finding that
autophagy moderates ER expansion in normal differentiating
PCs to their malignant counterparts.20
The present study provides a more comprehensive under-
standing of protein degradation in MM cells. In view of the tight
and multifaceted cooperation, documented herein, between
autophagy and the UPS, the data encourage us to integrate the
model currently proposed to underlie PI sensitivity, which exclu-
sively refers to the proteasomal workload and capacity,5 so as to
include autophagy in the functional assessment of MM cell biol-
ogy. The peculiar feature of being induced by PIs and specifically
digested by autophagy renders SQSTM1 an integrated reporter
of stress in both proteocatabolic routes, possibly indicative of
high susceptibility of myeloma cells to negative proteostasis regu-
lators, and particularly PIs. Indeed, we found that the presence of
SQSTM1C aggregates, as assessed biochemically or by immuno-
fluorescence, neatly discriminated between 2 groups of MM lines
or patients, characterized by differential inherent vulnerability to
PIs (Fig. 5). This striking correlation urges us to test SQSTM1
as a potential, highly needed single-cell prognostic tool to predict
individual clinical responses to PI treatment. The circumstance
that both the abundance and cellular distribution of SQSTM1
change under proteasome stress is likely to magnify its accuracy
as a reporter. Should this marker be able to predict the clinical
responsiveness to PIs, at least in selected groups of patients, a
new tool could be developed for clinical hematologists to help
inform the design of personalized therapeutic regimens.
Materials and Methods
Cell cultures
Human myeloma cell lines (kindly provided by Giovanni
Tonon, San Raffaele Scientific Institute, Milan, Italy) and B lym-
phoma cell lines (kindly provided by Paolo Ghia, San Raffaele
Scientific Institute, Milano, Italy) were cultured in RPMI
medium (Gibco-Life Technologies, 31860) supplemented with
10% fetal bovine serum (Euroclone, ECS0180L), L-glutamine
(2 mM; Gibco-Life Technologies, 25030–081), penicillin/strep-
tomycin (100 mg/ml; Lonza, 17–602E) and sodium pyruvate
(1 mM; Sigma-Aldrich, S8636). Each culture was examined for
Ig secretion and SDC1/CD138 expression, and periodically
tested for mycoplasma negativity. All lines are routinely geno-
typed by the Tonon lab using 2 protocols, one based on a set of a
microsatellite markers set in collaboration with the Mayo Clinic
(Scottsdale, AZ), and a second one, based on short tandem
repeats assessment, as developed by the DSMZ (details at http://
www.dsmz.de/services/services-human-and-animal-cell-lines/
online-str-analysis.html).
Patient-derived MM cells were purified from BM aspirates by
SDC1 immunomagnetic-positive selection using the Human
Plasma Cell Isolation kit (Miltenyi Biotech, 130–093–628).
Informed consent was obtained in accordance with the declara-
tion of Helsinki. Approval for use of primary samples was
obtained from the Institutional Review Board of the San Raffaele
Scientific Institute. Cells were treated with leupeptin,
Figure 6 (See previous page). A proteostatic autophagic reserve is saturated in PI-sensitive myelomas. (A) Immunoblotting analysis of the effect of 8-h
treatment with low dose (5 nM) bortezomib (Btz) on the accumulation of ubiquitinated proteins in the indicated panel of MM lines (representative blot,
n D 3). (B) The level of proteasome inhibition achieved in (A) was assayed in the indicated MM lines by means of a fluorogenic peptide specifically
cleaved by the proteasomal chymotryptic peptidase activity (% inhibition in one representative experiment). (C–E) Differential capacity of PI-sensitive
and -resistant MM cells to deploy autophagy against pharmacological proteasome stress. (C) Immunofluorescence analysis of SQSTM1 accumulation in
MM lines treated with 1 mM bortezomib (Btz) and 50 nM bafilomycin A1 (Baf A1), alone or in combination, for 1 h. Nuclei are stained blue with DAPI.
Scale bar: 10 mm. Representative images. (D) Average cellular counts of SQSTM1C puncta in the experiment shown in panel (C) (average §s.e.m., n  80
cells in 7 distinct fields). *P < 0 .05; **P < 0 .01; ***P < 0 .001 by unpaired Student t test. (E) Immunoblot analysis of SQSTM1 protein abundance in the
NP-40 soluble and insoluble cellular fraction (as in Fig. 5A) of the indicated MM lines treated as in panel (C). Equal protein amounts were resolved by
SDS-PAGE. Representative blots are shown (n D 3). (F) Immunoblot analysis of polyubiquitinated proteins in OPM2 cells subjected to the indicated pro-
teasome inhibition for 24 h, alone or combined with pharmacological (20 mM leupeptin, left panel) or genetic (lentiviral ATG7 RNAi as in Fig. S1) inhibi-
tion of autophagy (representative blots, n D 3).
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bafilomycin A1, chloroquine, rapamycin, hydroxychloroquine
(Sigma-Aldrich, L2884, B1793, C6628, R8781, H0915) or bor-
tezomib (Millennium, VELCADETM) as indicated.
Flow cytometric analyses of cell viability
Cells were treated as indicated, harvested and stained with
fluorescein isothiocyanate or allophycocyanin (APC)-conju-
gated ANXA5/annexinV (BD PharmMingen, 556547,
550474) and propidium iodide, as per the manufacturer’s
instructions. SDC1 positivity was controlled with anti-human
SDC1 APC conjugated anti-
body (Ab) (Miltenyi Biotec,
130–091–250). Data were
obtained with Accuri C6 Flow
Cytometer (BD biosciences,
San Jose, CA) and analyzed
using the FCS Express 4 Flow
Research Edition (De Novo
Software). Patient-derived MM
cells were seeded at 30,000 cells/well and treated for 24 h as
indicated.
Lentiviral RNA interference
Plasmid constructs expressing anti-ATG7, anti-SQSTM1, and
control shRNAs were obtained with Mission shRNAs pLKO.1-
puro (nontarget shRNA: SHC002; shATG7 1:
TRCN0000007584; shATG7 2: TRCN0000007587; shSQSTM1
1:TRCN0000007234; shSQSTM1 2: TRCN0000007236;
Sigma-Aldrich). Lentiviral vectors were packaged with Sigma-
Figure 7. Endoplasmic reticulum is
the main cell compartment
degraded by autophagy in MM
cells. (A) Proteome changes upon
autophagy inhibition (as in Fig. S4)
by SILAC LC-MS/MS. The 981 pro-
teins quantified in 2 independent
experiments were grouped by the
indicated gene ontology (GO) cate-
gories (average ratios §s.e.m.; sig-
nificance calculated against all
quantified proteins). (B) Immuno-
blot analysis of selected ER proteins
in MM cells treated with 100 nM
bafilomycin A1 (Baf A1) for 24 h
(representative image, n D 4). Top,
representative blots; bottom, quan-
tification normalized by ACTB/actin
expressed relative to untreated cells
(average §s.e.m., n D 4). (C) Rela-
tive protein abundance in MM.1S
vs. OPM2 cells by SILAC. The rela-
tive abundance of 1,674 proteins
was quantified in 2 independent
experiments. Proteins were
assigned to the corresponding GO
cell compartment (average GO val-
ues §s.e.m.). (D) ER morphology
was assessed in OPM2 and MM.1S
by electron microscopy and the
area of the cell occupied by the ER
was quantified by stereology. Left,
representative images; right, quan-
tification (average §s.e.m.; n  30
cells per line). Scale bar: 1 mm. (E)
Selected ER proteins were quanti-
fied in MM lines by immunoblot
analysis. Left, representative blots
(n D 4 independent experiments).
Right, average quantification §s.e.
m. *P < 0 .05; **P < 0 .01; ***P < 0
.001 by unpaired Student t test.
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Aldrich Mission shRNAs, pMD2-VSV-G, pMDLg/pRRE and
pRSV-Rev plasmids in HEK 293T cells for 14 h, then medium
was replaced and 1 mM Na-butyrate added. 48 h later cell super-
natant fractions were collected, ultracentrifuged, filtered and
administered to MM cells with polybrene (8 mg/ml; Sigma-
Aldrich AL-118) for 16 h. Transduced cells were selected for 1 wk
with 2 mg/ml puromycin (Sigma-Aldrich, P9620).
To assess shRNA toxicity, the gene encoding puromycin resis-
tance was replaced with GFP. The GFP-positive proportion of
viable cells for each shRNA was determined 3 d after infection
and then monitored by Accuri C6 Flow Cytometer (BD Bio-
sciences, San Jose CA) upon staining with APC-conjugated
ANXA5 (BD PharmMingen, 550474) and propidium iodide,
and normalized to initial values and nonspecific toxicity.
shRNA sequences. shATG7(1): CCGGGCCTGCTGAG-
GAGCTCTCCATCTCGAGATGGAGAGCTCCTCAGCAG
GCTTTTT; shATG7(2): CCGGCCCAGCTATTGGAACAC
TGTACTCGAGTACAGTGTTCCAATAGCTGGGTTTTT;
shSQSTM1 (1): CCGGCGAGGAATTGACAATGGCCATC
TCGAGATGGCCATTGTCAATTCCTCGTTTTT; shSQST
M1 (2): CCGGCCGAATCTACATTAAAGAGAACTCGAG
TTCTCTTTAATGTAGATTCGGTTTTT.
Colony-forming assay
Cells were resuspended in RPMI complete medium with
0.4% 2-hydroxyethylagarose (Sigma-Aldrich, A9414) at a con-
centration of 5,000 cells/well and plated over a 0.8% agar layer
in a 6-well plate. The experiment was performed in duplicate
and plates were incubated at 37C in a humidified incubator for
21 d. Upon staining with thiazolyl blue tetrazolium bromide
(Sigma-Aldrich, M2128) diluted 1:10 in 1X phosphate-buffered
saline (PBS; Euroclone, ECB4004L) for 4 h, colonies containing
at least 20 cells as assessed by light microscopy were counted.
Immunoblot analyses
Total cellular extracts were obtained by lysis in 150 mM
NaCl, 10 mM Tris-HCl (pH 7.5), 1% SDS (Sigma-Aldrich,
05030) for 15 min on ice. Genomic DNA was sheared by
30 min sonication.
To obtain soluble fractions, cells were collected and lysed in
150 mM NaCl, 10 mM Tris-HCl (pH 7.5) and 1% Nonidet
NP-40 substitute (Sigma-Aldrich, IGEPAL CA-630, I8896),
supplemented with protease inhibitors (30 mg; Roche,
05056489001), for 15 min on ice. Insoluble material was pel-
leted by centrifugation at 16,000 g for 15 min at 4C and resus-
pended in 150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 2% SDS
(Sigma-Aldrich, 05030). After lysis, proteins were quantified by
BCA assay. Proteins (30 mg) were resolved by 8%, 10%, 12% or
15% SDS-PAGE and blotted on nitrocellulose membrane (Bio-
Rad, 162–0115). Membranes were blocked in 5% milk in PBS,
0.1% Tween-20 (Sigma-Aldrich, 274348), incubated with pri-
mary and secondary antibodies, thoroughly washed with PBS,
0.1% Tween-20, and proteins revealed by ECL using a Chemi-
Doc-it (UVP) for HRP-conjugated secondary Ab or at FLA9000
(FujiFilm, Tokyo Japan) for Alexa Fluor conjugated secondary
antibodies (Life Technologies, A-21235, A-21036, A-21244,
A-21450). Band densitometric analysis was performed with
ImageJ free software (http://rsbweb.nih.gov/ij/). The following
Abs were used: guinea pig anti-SQSTM1 C-terminal polyclonal
Ab (1:1000 dilution; ProGen, GP62-C); rabbit anti-SQSTM1
(1:1000; Sigma-Aldrich, P0067); rabbit anti-MAP1LC3 poly-
clonal Ab (1:500; Novus Biologicals, NB100–220); rabbit anti-
ATG7 (1:1000; Sigma-Aldrich, A2856); anti-ACTB/b actin
(1:2000; Sigma-Aldrich, A5441); mouse anti-TUBA4A/a tubu-
lin (1:5000; Sigma-Aldrich, T6074); rabbit anti-P4HB (1:1000,
polyclonal antibody; kind gift of Ineke Braakman, Utrecht, NL);
goat anti-KEAP1 (1:200; Santa Cruz Biotechnologies,
sc-15246); mouse anti-ERP44 (1:1000; monoclonal Ab (36C9),
kind gift of Roberto Sitia, Milano, Italy); rabbit anti-PRDX4
(1:1000; AbFrontier, PA0009); mouse anti-Ub monoclonal Ab
(P4D1; 1:500; Santa Cruz Biotechnology, sc-8017).
SQSTM1 immunoprecipitation
Cells were collected and lysed in 150 mM NaCl, 10 mM
Tris-HCl (pH 7.5), 1% Nonidet NP-40 substitute, supple-
mented with protease inhibitors, incubated for 15 min on ice;
the nuclei were then pelleted at 1000 g for 15 min. Soluble
material was quantified and 10 mg protein lysate incubated for 2
pre-clearing cycles with 30 ml protein A Sepharose fast flow beads
(GE Healthcare, 17–0618–01) for 3 h. Pre-cleared lysate was
incubated for 16 h with 30 mg beads preconjugated with 5 mg
rabbit anti-SQSTM1 antiserum (Sigma-Aldrich, PA0067) or
control serum. Beads were washed 4 times in 150 mM NaCl,
10 mM Tris-HCl (pH 7.5), 0.1% Nonidet NP-40 substitute,
and resuspended in Laemmli buffer for SDS-PAGE resolution.
Immunofluorescence
MM cells were seeded on poly-l-lysine-coated slides, fixed
with 4% paraformaldehyde, and permeabilized with PBS 0.1%
Triton X-100. Cells were stained with guinea pig SQSTM1 anti-
sera (1:200), C-terminal (Progen, GP62-C), rinsed in PBS, and
stained with Alexa Fluor 488 goat anti-guinea pig IgG (1:500:
Life Technologies, A11073) and Hoechst 33,342 (Life Technol-
ogies, H3570). Images were acquired with Deltavision (Applied
Precision, Issaquah, WA) with an Olympus 60£ objective with a
numerical aperture of 1.42. For every sample several stacks were
acquired on the z-axis. Images were deconvoluted using Soft-
Works 3.5.0 (Applied Precision) and processed with ImageJ.
More than 80 cells per sample were counted and analyzed.
Intracellular ATP quantification
ATP was quantified with the luminescent CellTiter-Glo assay
per the manufacturer’s instructions (Promega, G7570), as
described.20 Briefly, for each condition 10,000 living cells were
plated in quadruplicate on white 96-well multiwell plates and were
analyzed with a Victor plate reader (Perkin-Elmer, Waltham MA).
Proteasome activity assays
Proteasome activity was determined using fluorogenic pepti-
des, as previously described.5,6 Briefly, cells were sonicated in ice-
cold buffer (50 mM Tris-HCl [pH 7.5], 1 mM DTT, 0.25 M
sucrose, 5 mM MgCl2, 0.5 mM EDTA, 2 mM ATP), and
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extracts were prepared by centrifugation (30 min 10,000 g, and
15 min 100,000 g). Proteasome-specific chymotryptic peptidase
activity was assayed by monitoring the production of 7-amino-4-
methylcoumarin (amc) from 100 mM Suc-LLVY-amc (Bachem,
I-1395) in 20 mM Tris-HCl (pH 7.5), 1 mM ATP, 2 mM
MgCl2, 0.2% bovine serum albumin. Reactions were started by
adding an aliquot of cell extract, and the fluorescence of released
amc (excitation, 380 nm; emission, 460 nm) was monitored
continuously at 37C with a Carry Eclipse spectrofluorometer
(Varian, Palo Alto, CA). Background activity (due to nonprotea-
somal degradation) was determined by addition of 10 mM
MG132 (Sigma-Aldrich C2211). Assays were calibrated using
standard free fluorophore solutions, and reaction velocities calcu-
lated from the slopes of the initial linear curve portions. Substrate
consumption at the end of incubation never exceeded 1%.
Electron microscopy
Cells were pelleted and processed as described.20 Ultrathin
sections were observed with a Zeiss Leo 912AB electron micro-
scope (Zeiss, Oberkochen Germany) operating at 80 kV. Digital
micrographs were captured with a 2kx2k Proscan slow-scan
charge-coupled device camera system (Proscan HSC2, Lagerlech-
feld Germany) controlled by the integrated Soft Imaging software
(Soft Imaging Software). ER was measured by stereography with
a fixed grid in ImageJ.
qRT-PCR
For RT-PCR, RNA was extracted from 1 £ 106 cells with
Trizol (Invitrogen, 10296028), 1000 ng RNA retrotranscribed
with ImProm-II Reverse Transcriptase (Promega, A3800), and
cDNA corresponding to 2–5 ng of original RNA used as tem-
plate in qPCR reactions.
qPCR were performed in 10 mL mix with 5 ml SYBR green I
master mix (Roche, 04707516001) on Roche LightCycler 480
and 1 ml 5 mM primers. Data were analyzed on Roche LC480
software with Advance Relative Quantification. Human H3
expression was used as normalizer in the analyses. Primers used
were: hATG7 FW: AGACAGAGGGCAGGATAGCA; hATG7
RV: TGGAACAAGCAGCAAATGAG; hHSPA5 FW:
TAGCGTATGGTGCTGCTGTC; hHSPA5 RV: TGACA
CCTCCCACAGTTTCA; hP4HBFW: TCACATCCTGCTG
TTCTTGC; hP4HB RV: GTCGCTGTCGATGAAGATGA;
hSQSTM1 FW: GGGGCGCCCTGAGGAACAGA; hSQSTM1
RV: CCTGGTGAGCCAGCCGCCTT; hXBP1s FW: CC
GCAGCAGGTGCAGG; hXBP1s RV: GAGTCAATACCGC-
CAGAATCCA; hXBP1 total FW: GCAAGCGACAGCGCCT;
hXBP1 total RV: TTTTCAGTTTCCTCCTCAGCG; hH3
FW: GTGAAGAAACCTCATCGTTACAGGCCTGGT; hH3
RV: CTGCAAAGCACCAATAGCTGCACTCTGGAA; hNB
R1 FW: GCGAGCTGAGAAGAAACAACG; hNBR1 RV:
GAAGGTGAGTCCCATCAGGC; hOPTN FW: TTCGGC
CTGGACAGAGAAAC; hOPTN RV: TGCCTTCTCTGC
TTGTAGCC.
SILAC mass-spectrometry
MM lines were grown in complete SILAC RPMI medium
(Thermo Scientific, 89984) supplemented with “light” (Lys0,
Arg0), “heavy” (Lys8, Arg10) or “intermediate” (Lys4, Arg6)
SILAC amino acids (arginine, Sigma-Aldrich, 643440, 608033;
lysine, Cambridge Isotope Laboratories, DLM-2640, CNLM-
291) for 14 d, with 95% mean labeling efficiency. Lysates were
loaded in SDS-PAGE, trypsin-digested, and analyzed using a
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific,
Waltham MA). For SILAC analyses of leupeptin effects, OPM2
cells were treated for 24 h with 20 mM leupeptin. Treated and
untreated cells differentially labeled were mixed 1:1 and lysed in
150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1% SDS for
15 min on ice. Samples were loaded on a 10% SDS-PAGE gel
and stained with colloidal Coomassie brilliant blue. Gel slices
were excised from the gel sampling the entire length of the lanes
from the direct and reverse experiments (12 slices each). For
MM.1S and OPM2 comparative analysis, differentially labeled
cells were mixed 1:1 and a cellular fractionation was performed
using the Qproteome Cell Compartment Kit (Qiagen, 37502).
Cytosolic, membrane and nuclear fractions were loaded on a
10% SDS-PAGE gel and 10 gel slices were excised from each
lane from the direct and reverse experiments. For SQSTM1
dynamic interactome SILAC, MM.1S cells were labeled with
“light,” “intermediate,” and “heavy” amino acids and IP per-
formed as described in Figure S2. Immunoprecipitates were
mixed 1:1:1 and loaded on a 10% SDS-PAGE gel and 10 gel
slices were excised and analyzed by LC-MS/MS. After reduction
with 10 mM DTT (Sigma-Aldrich, D9779), alkylation with
55 mM iodoacetamide (Sigma-Aldrich, I1149) and overnight
tryptic digestion, digests were desalted and concentrated on
C18 Stage Tips (Proxeon Biosystems, SP301) and then sepa-
rated on a NanoLC (EasyLC, Proxeon Biosystems, Odense
Denmark). Peptide separation occurred on a RP homemade 15-
cm reverse phase (RP) spraying fused silica capillary column
(75 mm i.d.), packed inhouse with 3-mm ReproSil-Pur 120
C18-AQ (Dr. Maisch GmbH, Germany). A gradient of eluents
A (H2O with 2% v/v ACN, 0.5% v/v acetic acid) and B
(80%ACN with 0.5% v/v acetic acid) was used to achieve sepa-
ration, from 7% B (at 0 min 0.2 mL/min flow rate) to 40% B
(in 70 min, 0.2 mL/min flow rate). The LC system was con-
nected to an LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientific, Waltham MA) equipped with a nanoelectrospray ion
source (Proxeon Biosystems, Odense, Denmark). MS and MS/
MS spectra were acquired selecting the 10 most intense ions per
survey spectrum acquired in the orbitrap from m/z 300–1750
with 30.000 resolution. Target ions selected for the MS/MS
were fragmented in the ion trap and dynamically excluded for
60s. For accurate mass measurements, the lock-mass option was
employed. Technical replicates were conducted on the LC-MS/
MS part of the analysis. Raw data were processed with Max-
Quant (version 1.2.2.5) and peptides identified from MS/MS
spectra against the Human Uniprot Complete Proteome Set
database (ver. 2012_05) using the Andromeda search engine.
Cysteine carbamidomethylation was used as fixed modification,
methionine oxidation and protein N-terminal acetylation as
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variable modifications. Mass deviation for MS/MS peaks was set
at 0.5 m/z units with a maximum of 2 missed cleavages allowed.
The peptides and protein false discovery rates were set to 0.01;
the minimal length required for a peptide was 6 amino acids;
minimum 2 peptides and at least one unique peptide were
required for high-confidence protein identification; for quantita-
tive analysis options Re-quantify and second peptide were
selected. The lists of identified proteins were filtered to elimi-
nate reverse hits and known contaminants.
Statistical and data analyses
For mass spectrometry, the Perseus software (v.1.1.1.21) was
used. Identification of significant protein changes required: i) sig-
nificance B at P < 0.05; ii) ratio normalized values concordant
in both direct and reverse experiments; iii) 2 ratio counts. Pro-
teins consistently upregulated were run through functional anno-
tation clustering on DAVID web resource, as described.20,51 For
general analyses of graphs and data, the Prism software, version
4.0 (GraphPad) was used. Statistical significance was tested with
a 2-tailed Student t test (a D 0.05). Figures were assembled with
Adobe Illustrator.
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